Biotech firm Cessatech reported an operating loss of DKK 3.8 million for the first quarter of 2026, compared to a loss of DKK 5.6 million in the prior-year period. The net loss amounted to DKK 3.2 million (vs. -4.3 million), while earnings per share came in at DKK -0.17 (vs. -0.25).

Revenue was nil for the quarter, down from DKK 2.4 million a year earlier. Cash and cash equivalents stood at DKK 5.3 million at the end of the period (vs. 6.6 million), with an equity ratio of 87 percent (vs. 39 percent).

CEO Jes Trygved stated that the company remains focused on completing the final steps ahead of the potential commercialization of CT001 in the U.S. and Europe.
Cessatech, MDKKQ1 2026Q1 2025Change
Revenue02.4
Operating profit-3.8-5.632.9%
Net profit-3.2-4.324.9%
Earnings per share, DKK-0.17-0.2532.0%